DETAILED METHODS
Methodological approach for quantitative benefit-harm assessment We modelled the benefit harm balance in different subgroups according to the Gail/National Cancer Institute (NCI) approach [1] that has been used in the past to estimate the benefit harm balance of tamoxifen for breast cancer prevention, of low dose aspirin for primary cardiovascular and cancer prevention [2, 3] , of roflumilast to prevent exacerbations in patients chronic obstructive pulmonary disease [4] and of systemic versus implant treatment of non-infectious uveitis [5] . As for most approaches for quantitative benefit harm assessment, this approach combines information on baseline incidence in the population (i.e. outcome risks) and relative effects of treatments. It also considers patients' preferences that reflect the relative importance of outcomes, and accounts for competing risks, and the statistical uncertainty of these input parameters through modelling.
In short, number of expected events Nx are calculated for both blood pressure targets (BP1 and BP2) and for each outcome x, from the baseline incidence and relative effects. Subsequently, an index is calculated as the weighted difference in event numbers, where wx is the weight for each outcome x in the formula below.
Accordingly, the best available evidence needed to be selected for the three key determinants for every subgroup: baseline incidence, relative treatment effect, and importance of outcomes. An advantage of the Gail/NCI approach is its transparency about the input parameters and the mathematical approach, which greatly facilitates sensitivity analyses. Sensitivity analyses are crucial to explore uncertainty in the overall quantitative benefit harm balance that arises from selecting the input parameters from different sources. How we selected the evidence, the crucial step in quantitative benefit harm assessment, is described in the following sections.
Relative effects Literature search method
Since a number of systematic reviews with meta-analyses were published recently we did not duplicate their entire search but identified relevant and recent systematic reviews first. We searched PubMed for recent systematic reviews of randomized clinical trials on blood pressure targets (published between 1.1.2015 and 9.26.2016). We used the following search string with a filter for systematic reviews: ( ). We excluded reviews that were not systematic and systematic reviews about blood pressure targets in acute conditions (intensive care setting). We considered one additional systematic review that was not yet published at the time. Eight systematic reviews were identified. Two reviewers (HEA, RFW) independently assessed the systematic reviews using the AMSTAR Checklist.
We appraised search strategies of the identified systematic reviews and updated searches of three systematic reviews through October 2016. All searches were designed to find studies on blood pressure targets, and were not restricted to subpopulations (e.g., diabetic patients only). If the systematic reviews included study designs other than RCTs we additionally applied a search filter for RCTs (Pub Med: "clinical trial" [pt] OR "controlled clinical trial"[pt] OR "randomized controlled trial" [pt] OR "metaanalysis" [pt] , Embase: (clinical and trial) or (randomized and controlled and trial) or (random and allocation) or ("single blind" and method) or ("double blind" and method), Cochrane: limited to Cochrane reviews, Web of Science: "clinical trial" OR "controlled clinical trial" OR "randomized controlled trial" OR "meta-analysis"). From the systematic reviews and their updated searches, we identified 20
RCTs comparing blood pressure targets in (non-pregnant) adults. Risk of bias for each of the 20 RCTs was assessed independently by two reviewers (HEA, OCS, RFW) using the Cochrane tool for risk of bias assessment. Disagreements in the assessments were resolved by discussion or third party adjudication. Study characteristics were extracted by two reviewers independently (OCS, RFW, TY). Data needed for the calculation of incidence rate ratios was extracted by two reviewers (HEA, OCS, RFW) independently.
Incidence rate ratios and their confidence intervals were calculated with Stata version 13.1. We included 3 RCTs in our analyses [6] [7] [8] [9] [10] , according to the inclusion criteria described above. All studies compared systolic blood pressure targets.
Literature search results
We identified eight systematic reviews published between January 1, 2015 and October 31, 2016 ( Figure  S1 ). [11] [12] [13] [14] [15] [16] [17] [18] We selected three of these systematic reviews with adequate search strategies to find RCTs on blood pressure targets ( Figure S2 ): two of them were based on search strategies designed to search specifically for RCTs comparing different blood pressure targets [16, 18] , and one was based on a broader search that included the terms "hypertension" or "blood pressure" [17] . Five reviews were not chosen to be updated. One was not originally designed to search for studies on blood pressure targets and only included names of antihypertensive drugs and drug classes. Three only considered part of the population of interest (diabetic or grade 1 hypertension). One provided a search strategy that was not reproducible; the review authors did not provide sufficient information to replicate the search they used.
Figure S1 Search for systematic reviews on blood pressure targets Twenty RCTs comparing blood pressure targets in an adult population were identified in the three included systematic reviews. The update searches yielded 1089 unique titles and abstracts ( Figure  S2 ). From those, we identified 3 additional studies, which were not new trials but two subgroup analyses of SPRINT and one report on CKD incidence in SPS3.
Amstar assessment of the three included systematic reviews: results We used AMSTAR to assess the quality of the systematic reviews we included in this benefit-harm analysis [16] [17] [18] . The three reviews were independently assessed by two trained and experienced reviewers. Assessments were compared and final determinations can be found below (Table S1 ).
In summary, all three reviews met the following assessment criteria: provided an a priori design; provided study characteristics; assessed and documented scientific quality of individual studies within the review; used appropriate methods to combine the findings of the individual studies. The three studies did not meet the following assessment criteria: provided a list of included and excluded studies; assessed the likelihood of publication bias. For the remaining criteria Kansagara [18] met all criteria but duplicate study selection and data abstraction; we could not assess this element. Xie [16] met all criteria but appropriate use of included study scientific quality; we could not assess this element, and this study did not include a conflict of interest statement. Ettehad [17] did not meet the criteria for three elements: comprehensive literature search, status of publication as an inclusion criteria; conflict of interest statement. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study ("low" or "high" is fine, as long as it is clear which studies scored "low" and which scored "high"; a summary score/range for all studies is not acceptable). for the systematic review AND for each of the included studies.
RCT selection
We included randomized clinical trials (RCTs) that compared at least two different (diastolic or systolic) blood pressure targets in patients with hypertension. RCTs had to include at least one of the outcomes all cause death, myocardial infarction, stroke, heart failure, end stage renal disease, and one of the outcomes acute renal failure, CKD, cognitive function impairment, hypotension, dizziness, syncope, injurious falls. We excluded an RCT in patients with autosomal dominant polycystic kidney disease, because this was not our target population [19] . We assessed risk of bias for the remaining 19 RCTs using the Cochrane Risk of Bias Tool [20] (assessment in Table S2 ) and excluded RCTs with high risk of bias and did not use estimates for outcomes with high risk of bias [21] [22] [23] . We did not include RCTs where very few events were reported for all outcomes (less than 5 in at least one treatment arm) in our analyses [24] [25] [26] , or only very few events for all harm outcomes [27] . We did not include one RCT in our analyses that compared blood pressure targets of <150/85 to <180/105, as there is high-strength evidence that reducing blood pressure to <150 is beneficial, and the comparison is not a relevant one anymore [28] . Finally, we excluded two RCTs from the analysis because they reported so few outcomes (4 and 5 of the 13 outcomes we wanted to include: mortality, myocardial infarction, stroke, CKD in both, and heart failure additionally in one case), and in particular did not report many outcomes that favour higher blood pressure target (hypotension, syncope, injurious falls, acute kidney injury), that we could not use their information to calculate a reliable estimate of the benefit harm balance [9, 10] (see also Figure S3 ). 
Figure S3 Selection of RCTs comparing systolic blood pressure targets for inclusion in the analysis
Selection of treatment effect estimates for the benefit harm model We classified the RCTs according to age, prevalence of diabetes, CKD and stroke at baseline in the study population. Gender distributions were similar across all studies, and heart failure was always rare at baseline. Choosing the most appropriate trial(s) for each subgroup, we applied incidence rate ratios from SPRINT (which included people aged 50 years or older with an 10-year cardiovascular risk of 15% or greater but no prior history of stroke or diabetes) to non-diabetic subgroups with no prior history of stroke, those from ACCORD (which included people with diabetes type 2 aged 40 or older with increased cardiovascular risk) to diabetic subgroups with no prior history of stroke, and those from SPS3 (which included people aged 30 or older with recent lacunar stroke) to subgroups with prior history of stroke but no history of chronic kidney disease (CKD), with some exceptions (see also Table 1 in the main paper for an overview):
 End stage renal disease from ACCORD: The outcome was measured in people with CKD and without CKD at baseline. This may have changed the treatment effect, because CKD incidence is higher with lower blood pressure, but ESRD incidence in people with CKD is lower with lower blood pressure. Instead, we always took the treatment effect estimate from SPRINT, which measured ESRD incidence in participants with CKD at baseline only.  CKD from SPRINT: SPRINT measured incident reduction in estimated glomerular filtration rate (eGFR) of at least 30% to <60 ml / min / 1.73m 2 . As typically people with eGFR 30-60 do not experience symptoms, we chose to always assume the treatment effect estimate from ACCORD instead, which reported incident eGFR <30 ml / min / 1.73m 2 .  Hypotension from ACCORD: As in the 120 mmHg group, there were 17 events of hypotension SAE, but in the 140 mmHg group only 1 case, this gives an IRR of approximately 17. However, if there were just one more case in each arm, the IRR would be about half of this. This phenomenon is called sparse data bias [29] . It can be dealt with by assuming a prior IRR [30] assumed a prior IRR between 1 and 5. I.e., we expect that there are more hypotension events in the lower treatment group, but we would not have expected more than 5 times as many. In comparison, in SPRINT the RR was approximately 1.7. We assumed that diabetic patients may be more prone to hypotension, and therefore set the upper limit to 5. The resulting (Bayesian) IRR is 2.6.  As injurious falls and acute kidney injury were not reported by ACCORD, we assumed the relative treatment effect from SPRINT was also valid for people with diabetes.  Injurious falls from SPS3: As there were 0 events in the 150 group and 3 events in the 130 group, the IRR is affected by sparse data bias. As in SPRINT a HR of 1.00 was reported We did not include dizziness because it was not monitored in any of the studies. We did not include cognitive impairment. SPS3 reported the same incidence of mild cognitive impairment for both blood pressure targets, but the definition of mild cognitive impairment was derived in post-hoc analysis [31] . We did not include treatment burden in the main analysis, because the relative risk of having significantly more treatment burden with a lower target was not reported.
Results from SPRINT indicate age is not an effect modifier [32] , thus we extrapolated the relative effects to other age groups. Subgroup analyses for people with heart failure should be interpreted carefully, as these patients were not well represented in the trials. We do not present a benefit harm balance for subgroups with stroke and CKD at baseline, as the evidence was insufficient. We extracted information on possible effect modification from the trial's publications: there was no evidence for heterogeneity of treatment effects for our outcomes of interest according to our baseline characteristics of interest.
Baseline incidence
To address outcome baseline incidences for people with hypertension according to age, gender and history of stroke, diabetes, heart failure and CKD, we prioritized evidence from different sources in the following order as has been suggested previously [33] : 1. Evidence from US national registries that reflect the target population as closely as it is possible. 2. Evidence from observational study with similar study population as the target population. 3. Evidence from randomized clinical trials. Incidence rates may be different in the RCTs compared to those in observational studies because of differences in the sample, due to restrictive inclusion criteria or recruitment procedures.
Because 140 mmHg has been the most widely recommended systolic blood pressure target in the last 30 years, we expect that national registries and observational studies best describe the baseline incidence for a systolic blood pressure target of 140 mmHg. Accordingly, we took 140 as the reference target. Table S3 illustrates summarizes the sources of evidence and illustrates which subgroup variables influence the baseline incidence in the model. To estimate mortality (which we considered as a competing risk) we relied on Centers for Disease Control estimates [34] . We also took age and gender distributions from national data [45] , and estimated the prevalence of diabetes (12% for age 50-64, 21% for age 65-74, and 19.2% for age 75-84) and of risk factors such as current smoking (17% current smokers in age range 50-64, 8.4% current smokers for people 65 and older, 23% former smokers in all age ranges) from national data [46, 47] , and assumed 85.3% of people in the US are white and 14.7% are black as a simplification [48] . In order to define the baseline incidence rates of all outcomes other than mortality across all planned subgroups, we used prediction models based on observational studies when available. Differences in study populations of observational studies for different outcomes can result in inconsistent incidence estimates for different outcomes. Therefore, we only used prediction models developed at least in part based on data from the Atherosclerosis Risk in Communities (ARIC) study [40, 41, 43] , with the exception of end-stage renal disease (ESRD) [49] , for which we used a prediction model based on a retrospective cohort study in patients with CKD. We assumed that people first develop CKD, and only then are at risk to develop ESRD. Participants of ARIC were not all hypertensive, but hypertension, antihypertensive therapy or SBP is usually included in prediction models, and the incidence should therefore apply to people with hypertension. We took the incidence of acute kidney injury from incidence tables [44] . For myocardial infarction, there was no prediction model available (only for coronary heart disease, a combined outcome), and we used incidence tables according to age and gender [35] and assumed a 2 fold increase with diabetes at baseline [37] , a 2 fold increase with heart failure at baseline [38] , a 2.1 fold increase with stroke at baseline [39] , and a 1.38 fold increase with CKD at baseline [36] . Because CKD or eGFR was not included as a predictor variable in the prediction models for heart failure and stroke, we corrected the incidence in subgroups with CKD with factors of 1.68 and 1.12, respectively [36] , in the main analysis, and omitted the factors in a sensitivity analysis.
Information on (serious adverse events or emergency department visit due to) injurious falls, hypotension and syncope was not available from ARIC. Therefore, we used age-stratified baseline incidence calculated from SPRINT (incidence in 1000 person-years: hypotension, age 50-64: 5.2, age 65-74: 6.0, age 75+: 8.7, syncope, age 50-64: 6.0, age 65-74: 5.8, age 75+: 12.7, injurious falls, age 50-64: 11.1, age 65-74: 15.8, age 75+: 50.1). For the subgroup with stroke at baseline, we took the incidence of recurrent stroke from the SPS3 study [8] , as the prediction model was not for recurrent stroke.
In order to calculate the baseline risk of stroke, heart failure, CKD and ESRD with prediction models, we needed to make assumptions about the prevalence of some predictor variables. Based on our population of interest, we defined that everyone has hypertension and takes antihypertensive medication. We relied on ARIC when possible: a prevalence of CHD of 4.1% in people without heart failure at baseline, a prevalence of anaemia of 2%, a mean BMI of 27.55 kg/m 2 , a mean heart rate of 66.5 bpm, a distribution of eGFR values in CKD patients with 3% having eGFR 15-29 ml / min / 1.73m 2 , 15% having eGFR 30-44 and 82% having eGFR 45-59 and uniform distributions within these categories. Further assumptions we made that were not based on ARIC included assumptions on left ventricular hypertrophy (LVH) and peripheral artery disease (PAD). We assumed no one without heart failure has LVH, and 47% of people with heart failure have LVH [50] . We defined the prevalence of peripheral artery disease by age: 2.6% with age 50-59, 7.3% with age 60-69, 12.6% with age 70-79, and 30.8% with age 80-89 [51] . Because we were interested in symptomatic CKD, but the prediction model for incident CKD predicts incident eGFR < 60 mL/min/1.73m 2 , which for most patients is not symptomatic, we reduced the incident CKD cases in our main analysis by a factor of 5.15 in accordance with the incidence of eGFR <30 mL/min/1.73m 2 in the ACCORD study. In an additional analysis to inform the range of possible estimates (presented as a range in Table S5 ), we reduced the incidence of CKD by an additional factor of 2.
Relative importance of outcomes
We used a multi-step, mixed-methods process to elicit preferences to understand which outcomes are meaningful to patients. We used information gathered in the previous portion of this project to identify patient-important outcomes: acute kidney injury, chronic kidney disease, cognitive impairment, endstage renal disease, falls, myocardial infarction, heart failure, low blood pressure, dizziness, more treatment burdens, syncope, stroke and death (PMID: 28349409). These outcomes have been chosen after input from qualitative research with patients and caregivers about what outcomes were deemed important to them and a literature review of outcomes that have been used in relevant clinical trials. We surveyed patients with multiple chronic conditions and hypertension using best-worst scaling. The results of this survey will be reported elsewhere.
For the main analysis, we based weights on the parameters of the conditional logit model applied to the survey data (on the log scale). We performed a series of a sensitivity analyses in order to explore how much the choice of weights affected the benefit harm balance (see section Sensitivity analyses).
Expected number of events in 5 years
We calculated the number of expected events over 5 years in a population of 10 000. Number of events with a target of <140 (or 131-150) mmHg were based on the baseline incidence only, whereas for <120 and <130 mmHg, the calculation also took into account the relative treatment effect estimates. All-cause mortality was considered as a competing risk for all other outcomes. We considered uncertainty of estimates in relative effects and distributions in baseline risks (due to distributions of risk factors accounted for in prediction models) in 100 000 repetitions in the analysis.
We used the following equations, were t is the time, Ix is the baseline incidence for outcome x, M is mortality, Rx is the relative effect for an outcome x and Rm is the relative effect on mortality. While for the benefit harm assessment in the general population, we used an estimate of ESRD incidence from a mixed CKD/no CKD population, for the subgroups, we assumed that only people who had developed CKD were at risk to develop ESRD. In subgroups with CKD (eGFR < 60 ml/min/1.73m
2 ) at baseline, that corresponded to the whole population. In subgroups without CKD at baseline, we calculated the person-time of CKD (eGFR < 60 ml/min/1.73m 2 ) due to CKD incidence over time, and multiplied it with the incidence rate of ESRD as an estimate of incidence of ESRD.
Consideration of statistical uncertainty in parameters
For the 100 000 repetitions, we sampled relative effects from normal distributions over the confidence interval. When the imprecision in the relative effect would lead to rating down by two levels in a GRADE assessment, instead of normal distributions, we sampled from uniform distributions over the confidence interval. For baseline incidences in subgroups calculated from prediction models with additional predictor variables, we assumed distributions in these predictor variables and generated 100 000 different combinations (assuming independence between the variables). Accordingly, 100 000 different baseline risks were predicted, reflecting that individuals in the subgroups do not all have the same riskfor example, smokers have higher risks than non-smokers.
Calculation of a range of possible estimates
To define a range of possible estimates of the benefit harm balance, we performed two analyses taking into account uncertainty in the baseline incidence. One favoured the lower target, in which we assumed a lower incidence of symptomatic CKD, and a greater increase in the incidence of myocardial infarctions due to prior history of diabetes (3-fold instead of 2-fold increase). The other favoured the upper target, in which we did not correct stroke and heart failure incidence for CKD at baseline, and we assumed that over the years, the incidences of myocardial infarction and stroke have decreased, by a factor of 0.665 in men and 0.73 in women for myocardial infarctions [52] , and by a factor of 0.7 for men and 0.72 for women for stroke [53] .
Sensitivity analyses
To investigate the influence of different preferences, we performed the following sensitivity analyses: we performed sensitivity analyses with different weights, based on the exponents of the conditional logit parameters (sensitivity analysis 3), the best-minus-worst scores (sensitivity analysis 4), the surface under the cumulative ranking curve (SUCRA scores, sensitivity analysis 5) (all based on the survey) and with equal weights (sensitivity analysis 6), as a reference (Table S4) . 
Weights are based on different analyses of the best-worst scaling preference survey among people with MCC: exponents of the conditional logit parameters (sensitivity analysis 3), best-minus-worst scores (sensitivity analysis 4), the surface under the cumulative ranking curve (SUCRA) (sensitivity analysis 5) (all based on the survey) and with equal weights (sensitivity analysis 6). We chose weights based on the conditional logit parameters on the log scale (logOR) as the main analysis because this is best established to calculate utilities [54]. Best-minus-worst scores are simple count scores. SUCRA are scores between 0 and 1, calculated from the probability that an outcome has a certain rank or a higher one, based on the mean differences between bestminus-worst scores between outcomes in a network meta-analysis model. CKD= Chronic kidney disease. ESRD= End-stage renal disease, AKI= Acute kidney injury.
Best-minus-worst scores can be calculated for every individual and can be used to describe the variability in individual preferences. However, these scores, which are simple count scores, are less well suited to describe the relative importance of outcomes compared to the conditional logit parameters. Therefore, to estimate the impact of variation in individual preferences on the benefit harm balance, we calculated weights for every individual based on best-minus-worst scores, scaled according to the conditional logit parameters and the average best-minus-worst scores, keeping the individuals' ranking of outcomes as in the best-minus-worst scores (sensitivity analysis 1 and 2). In sensitivity analysis 2 we additionally included treatment burden, assuming 20% of people have more treatment burden with the lower target than with 140 mmHg.
We included treatment burden only in a sensitivity analysis, where we assumed that 20% of people would experience more treatment burden (corresponding to two extra tablets per day, more doctor appointments, regular blood pressure measurements, regular physical activity and diet) with the lower than with the higher target. We assumed increasing the dose would not increase the treatment burden, and that this would be enough for most people. Furthermore, in the survey, 18% of respondents always chose treatment burden as the least worrisome outcome, implying this perhaps is not worrisome to them at all. Trials cannot report how many participants have more treatment burden when participants are always assigned to the same target. While trials reported an average of approximately one more antihypertensive medication with lower targets, this does not mean every participant had one more pill than he or she would have in the other arm. The mean index from the main analysis (Table 3 in the manuscript) is shown in Table S6 . Sensitivity analyses 3-6: Impact of different population average preference weights To investigate the influence of different weights, we performed the following sensitivity analyses: Sensitivity analyses 3-5 with different weights based on different analyses of the survey; sensitivity analysis 6 with equal weights for all outcomes (a list of all weights is in Table S4 ). Best-minus-worst scores are simple count scores. The surface under the cumulative ranking curve (SUCRA) scores are scores between 0 and 1, calculated from the probability that an outcome has a certain rank or a higher one, based on the mean differences between best-minus-worst scores between outcomes in a network meta-analysis model.
Benefit harm balance of 120 mmHg vs 140 mmHg for people without prior stroke In sensitivity analysis 3 (Table S7) , which gave less weight to harms, 120 mmHg was better in more subgroups than in the main analysis. Sensitivity analyses 4, 5 and 6 (equal weights) gave more weight to the harm outcomes (CKD, AKI, injurious falls, hypotension and syncope), and accordingly favoured 140 mmHg more often than the main analysis (Tables S8-11 ). When taking into account sensitivity analyses 3-5, the classification (120 mmHg better, 140 mmHg better, unclear which target is better) always remained the same (120 mmHg better) as in the main analysis for 30 of 96 subgroups without prior stroke (Table S10) .
Benefit harm balance of <130 vs 131-149 mmHg for people with prior ischemic stroke The probability that <130 mmHg is better than 131-149 mmHg in people with prior ischemic stroke was greatly affected in all subgroups by using different weights, as shown in sensitivity analyses 3-6 (Tables  S7-11 ). Using equal weights for all outcomes (sensitivity analysis 6), a target of 131-149 mmHg was better for all subgroups with prior ischemic stroke, with probabilities of 0.07 to 0.26 of <130 mmHg being better than 131-149 mmHg. Comparing sensitivity analyses 3-5 with the main analysis, the classification always remained the same for only 1 of 24 subgroups with prior stroke: "unclear which target is better" (Table S10) . 
